Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT). 

InnoBio Fund

Inserm Transfert Initiative

Sensorion

Decibel Therapeutics is a biotechnology company focused on discovering and developing new therapies to protect, repair, and restore hearing.

Decibel Therapeutics

Frequency Therapeutics is a biotechnology company that develops small molecule drugs to activate progenitor cells within the body to restore healthy tissue.

Frequency Therapeutics

Akouos is a biotechnology company dedicated to developing gene therapies to restore and preserve hearing.

Akouos

Sensorion is a clinical-stage biotech company specializing in the development of novel therapies to restore, treat, and prevent hearing loss disorders, addressing a significant global unmet medical need. The company has a strong focus on R&D and has built a technology platform to expand its understanding of inner ear-related diseases, enabling the selection of the best targets and modalities for drug candidates.

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

Sensorion SA

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Feb 9, 2024 11:37 AM	f89d7f4d
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 9, 2024 11:37 AM	b0725a1b
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
peers	general	Feb 9, 2024 11:37 AM	94e3a793
news basic	general	Feb 9, 2024 11:37 AM	a60abcf1
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
logo	meta
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:SENSORION

Sensorion

Last Close

0.77

25/09 14:03

Market Cap

210.24M

Beta: -

Volume Today

153.90K

Avg: -